Home > Insider Trading > Filing (0001209191-18-016034)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	980505495

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1675881	Y David Liu	C/O Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark CA 94560-1160	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-02-28	9,500	$0.00	13,322	No	4	A	Direct
Common Stock	Acquisiton	2018-03-02	875	$1.89	14,197	No	4	M	Direct
Common Stock	Disposition	2018-03-02	875	$20.00	13,322	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2018-02-28	56,500	$0.00	56,500	$16.95
Common Stock	Employee Stock Option (right to buy)	Disposition	2018-03-02	875	$0.00	875	$1.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
56,500		2028-02-27	No	4	A	Direct
9,725		2024-10-22	No	4	M	Direct

Footnotes

Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017.
The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years.
The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date.